Setmelanotide vs Mazdutide
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Imcivree, RM-493
Setmelanotide (brand name Imcivree) is a melanocortin-4 receptor (MC4R) agonist peptide and a genuine FDA-approved obesity drug, first cleared in 2020. It is not a general weight-loss shot like the GLP-1 drugs: it is a targeted therapy for rare genetic forms of severe obesity where a specific brain hunger circuit is broken. It is given as a once-daily subcutaneous injection and has since been approved for additional conditions including Bardet-Biedl syndrome and acquired hypothalamic obesity.
Also: IBI362, LY3305677
Mazdutide is a GLP-1 and glucagon dual agonist, which puts it between semaglutide (GLP-1 only) and retatrutide (GLP-1, GIP and glucagon). It is built on oxyntomodulin, a natural gut hormone that hits both receptors, rather than on a GLP-1 backbone. It is furthest along in China, where it is approved for both weight management and type 2 diabetes. Western approval has not happened.
Key Comparison Insights
- Setmelanotide is FDA approved, while Mazdutide remains in research stages.
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
- Setmelanotide has stronger research evidence (FDA Approved) compared to Mazdutide (Human Trials).
Detailed Comparison
| Attribute | Setmelanotide | Mazdutide |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Deep in the hypothalamus there is a pathway that tells your brain you are full and that ramps up energy use. It runs through signals like leptin and POMC down to the MC4R receptor. In people with certain rare gene defects, such as POMC, PCSK1, or LEPR deficiency, that pathway is short-circuited upstream of MC4R, so the brain never gets the fullness signal and hunger is relentless. Setmelanotide bypasses the broken upstream step by binding and switching on MC4R directly, restoring the satiety and energy-expenditure signal. That is why it works specifically in these genetic and syndromic forms of obesity and would not be expected to fix common obesity the same way. | Two receptors, two jobs. The GLP-1 arm does the familiar work: it suppresses appetite, slows gastric emptying and improves glucose-dependent insulin release. The glucagon arm is the interesting half, because glucagon is normally thought of as the hormone that raises blood sugar. At these doses the intent is to exploit glucagon's other effects, increasing energy expenditure and pushing the liver to burn fat, while the GLP-1 arm keeps blood glucose in check and cancels out glucagon's hyperglycemic tendency. That balance is the whole design: glucagon supplies extra fat burning that GLP-1 alone cannot, and GLP-1 supplies the safety margin that makes adding glucagon viable. Reported reductions in liver fat are consistent with the glucagon component doing what it is meant to. |
| Common Dosing | 2-3 mg daily Once daily | 4-6 mg weekly Once weekly |
| Administration | Subcutaneous injection daily | Subcutaneous injection, once weekly |
| Typical Duration | Long-term / chronic use | Ongoing weekly use in trials, typically assessed at 24 to 48 weeks |
| Best Time to Take | Before bed or morning (fasted) | Same day each week, morning preferred |
Possible Side Effects May vary by individual |
|
|
| Research Summary | The human evidence is strong but deliberately narrow, matching the rare diseases it treats. The pivotal single-arm, open-label phase 3 trials in POMC and LEPR deficiency, published in The Lancet Diabetes and Endocrinology in 2020, reported that 80 percent of POMC patients and 45 percent of LEPR patients achieved at least 10 percent weight loss at about one year, alongside large drops in hunger scores. A separate randomized, placebo-controlled phase 3 trial supported approval in Bardet-Biedl syndrome, and a 2024 open-label trial (VENTURE) extended evidence to children as young as two. The trials were small because these conditions are extremely rare, so the data are best read as convincing within those specific genetic populations rather than as evidence for obesity broadly. The common side effects are consistent and manageable: skin hyperpigmentation, injection-site reactions, nausea, and headache, with no serious treatment-related events reported in the core trials. This is a legitimate approved drug for defined genetic indications, not an off-label general weight-loss peptide. | The pivotal trial is GLORY-1, published in the New England Journal of Medicine in 2025: 610 Chinese adults with overweight or obesity over 48 weeks. Mean weight reduction was 11.0 percent at 4 mg and 14.0 percent at 6 mg, alongside improvements in liver fat, blood pressure and lipids. A 9 mg dose has since been studied in phase 2 (about 12.8 percent at 24 weeks) and is in phase 3. Tolerability followed the pattern of the whole class, dominated by dose-dependent nausea, vomiting and diarrhea during titration. One caveat matters when reading these numbers: GLORY-1 enrolled a population with a mean BMI of 31.1, against roughly 38 in the Western trials of semaglutide and tirzepatide, so the percentages are not directly comparable to SURMOUNT-1 or STEP-1 results. There is no completed Western phase 3 program, so neither the FDA nor the EMA has assessed it, and meaningful head-to-head data against tirzepatide or retatrutide does not exist. |
Frequently Asked Questions: Setmelanotide vs Mazdutide
What is the difference between Setmelanotide and Mazdutide?
Setmelanotide is a weight loss peptide that setmelanotide (brand name imcivree) is a melanocortin-4 receptor (mc4r) agonist peptide and a genuine fda-approved obesity drug, first cleared in 2020. it is not a general weight-loss shot like the glp-1 drugs: it is a targeted therapy for rare genetic forms of severe obesity where a specific brain hunger circuit is broken. it is given as a once-daily subcutaneous injection and has since been approved for additional conditions including bardet-biedl syndrome and acquired hypothalamic obesity. Mazdutide is a weight loss peptide that mazdutide is a glp-1 and glucagon dual agonist, which puts it between semaglutide (glp-1 only) and retatrutide (glp-1, gip and glucagon). it is built on oxyntomodulin, a natural gut hormone that hits both receptors, rather than on a glp-1 backbone. it is furthest along in china, where it is approved for both weight management and type 2 diabetes. western approval has not happened. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Setmelanotide or Mazdutide?
Neither is universally "better" - the choice depends on your specific goals. Setmelanotide is typically used for weight loss purposes, while Mazdutide is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Setmelanotide and Mazdutide be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Setmelanotide and Mazdutide together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.